1. HBW Insight
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

Sanofi Switch Gives UK Hay Fever Sufferers Additional Mass Market Option

 
• By David Ridley

Sanofi has switched its Allevia hay fever tablets (fexofenadine hydrochloride) in the UK, from prescription-only to general sales list status. 

Hayfever
• Source: Shutterstock

UK hay fever sufferers will soon be spoiled for choice outside pharmacy thanks to another prescription-only to general sales list (POM-to-GSL) switch, this time from Sanofi.

Following hot on the heels of Johnson & Johnson’s POM-to-GSL switch of Benacort Hayfever Relief (64μg budesonide), the UK Medicines and Healthcare products Regulatory Agency has now also approved Sanofi’s Allevia 120mg Tablets (fexofenadine hydrochloride) for sale outside pharmacy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

Over The Counter: Brands, Brexit And New Self-Care Business Models, With PAGB’s Michelle Riddalls

 
• By David Ridley

HBW Insight catches up with UK OTC industry association CEO Michelle Riddalls to talk about digital self-care and the unrealized promise of Brexit - part 2.

Clasado Divests Bimuno Prebiotic Consumer Brand To UK’s Eleat

 
• By David Ridley

Eleat's acquisition encompasses Clasado's Bimuno finished supplement product line and customer base, but not its Bimuno GOS proprietary galactooligosaccharide prebiotic ingredient.

‘The Only Certainty Is Uncertainty’ In The UK’s Consumer Health Market

 
• By David Ridley

While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.

More from Europe

OTCs Are ‘Beacon Of Hope’ For Austrian Pharmacy

 
• By David Ridley

Just under half of Austrian pharmacists surveyed by Elpato Medien are “convinced that the OTC business will ensure the survival of their pharmacy.”

Over The Counter: Brands, Brexit And New Self-Care Business Models, With PAGB’s Michelle Riddalls

 
• By David Ridley

HBW Insight catches up with UK OTC industry association CEO Michelle Riddalls to talk about digital self-care and the unrealized promise of Brexit - part 2.

Plenty For Industry To Do As EU Wastewater Directive Faces Legal Challenges

 
• By David Ridley

Engaging with EU member state legislators, stressing the impact of national EPR systems on the accessibility, availability, and affordability of medicines, reformulating products to reduce their financial contribution, and lobbying for expanding the scope of EPR schemes to include other polluting industries are all ways that the European consumer health industry can try and influence the way that the revised Urban Wastewater Treatment Directive is transposed into national legislation, law firm Mason Hayes & Curran explains.